These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17296456)

  • 1. The relation between intermittent dosing and adherence: preliminary insights.
    Kruk ME; Schwalbe N
    Clin Ther; 2006 Dec; 28(12):1989-95. PubMed ID: 17296456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of once- and twice-daily dosing regimens on adherence and overall safety.
    Hawkins T
    AIDS Read; 2004 Jun; 14(6):320-2, 324, 329-31, 334-6. PubMed ID: 15243968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily dosing of nevirapine in HAART.
    Clotet B
    J Antimicrob Chemother; 2008 Jan; 61(1):13-6. PubMed ID: 18006524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence.
    Cramer JA
    Am J Manag Care; 1998 Nov; 4(11):1563-8. PubMed ID: 10338902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey.
    Granger AL; Fehnel SE; Hogue SL; Bennett L; Edin HM
    J Affect Disord; 2006 Feb; 90(2-3):217-21. PubMed ID: 16360216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study.
    Parienti JJ; Massari V; Reliquet V; Chaillot F; Le Moal G; Arvieux C; Vabret A; Verdon R;
    AIDS; 2007 Oct; 21(16):2217-22. PubMed ID: 18090049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive perspective on patient adherence to topical glaucoma therapy.
    Tsai JC
    Ophthalmology; 2009 Nov; 116(11 Suppl):S30-6. PubMed ID: 19837258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medication adherence in chronic disease: issues in posttransplant immunosuppression.
    Hansen R; Seifeldin R; Noe L
    Transplant Proc; 2007 Jun; 39(5):1287-300. PubMed ID: 17580126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosing frequencies in general practice--Whose decision and why?
    Saltman DC; Sayer GP; O'Dea NA
    Aust Fam Physician; 2006 Nov; 35(11):915-9. PubMed ID: 17099815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence in dermatology: a review of the last 20 years.
    Hodari KT; Nanton JR; Carroll CL; Feldman SR; Balkrishnan R
    J Dermatolog Treat; 2006; 17(3):136-42. PubMed ID: 16854752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use.
    Robin AL; Novack GD; Covert DW; Crockett RS; Marcic TS
    Am J Ophthalmol; 2007 Oct; 144(4):533-40. PubMed ID: 17686450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
    Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
    J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial.
    Rand C; Bilderback A; Schiller K; Edelman JM; Hustad CM; Zeiger RS;
    J Allergy Clin Immunol; 2007 Apr; 119(4):916-23. PubMed ID: 17349681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dosing frequency on chronic cardiovascular disease medication adherence.
    Coleman CI; Roberts MS; Sobieraj DM; Lee S; Alam T; Kaur R
    Curr Med Res Opin; 2012 May; 28(5):669-80. PubMed ID: 22429067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of fluconazole for the treatment of onychomycosis.
    Brown SJ
    Ann Pharmacother; 2009 Oct; 43(10):1684-91. PubMed ID: 19776299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?
    Cohen AT; Maillardet L; Yavin Y
    Thromb Haemost; 2009 Mar; 101(3):422-7. PubMed ID: 19277401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferences of patients receiving bisphosphonates--how to influence the therapeutic adherence.
    Payer J; Killinger Z; Sulková I; Celec P
    Biomed Pharmacother; 2008 Feb; 62(2):122-4. PubMed ID: 17888616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.